**Johnson Pharmacare Limited** (formerly known as **Sun and Shine Worldwide Limited**) is an Indian entity listed on the **BSE (Scrip Code: 532154)**. The company is currently navigating a transitional phase, attempting to pivot from a period of operational dormancy toward a centralized management model focused on pharmaceutical supply chains, international trade, and aggressive capital allocation. --- ### **Core Business Capabilities & Operational Focus** The company’s business model is built around five board-identified core competencies designed to support its industrial and commercial functions: * **Manufacturing & Supply Chain:** Oversight of production facilities and end-to-end logistics management. * **Project Management:** Specialized focus on the timely delivery of industrial equipment and the expansion of physical infrastructure. * **B2B Sales & Marketing:** Dedicated account management and business-to-business sales strategies. * **International Business:** Strategic expansion into new global geographies and cross-border trade. * **Technical Talent Management:** Focus on engineering skills and industrial relations to support technical operations. --- ### **Financial Performance & Capital Structure** The company is currently in a state of **minimal operational activity**, reporting **no revenue from operations** for the consecutive financial years ending March 2024 and March 2025. Financial performance is characterized by widening net losses driven by administrative overheads. #### **Comparative Financial Summary** | Metric | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Revenue from Operations** | **Nil** | **Nil** | | **Net Profit / (Loss)** | **(Rs. 58,38,085)** | **(Rs. 19,62,247)** | | **Dividend Recommended** | **Nil** | **Nil** | | **Cash Losses** | **Incurred** | **Incurred** | #### **Balance Sheet & Asset Composition (As of March 31, 2024)** Despite the lack of active revenue, the company maintains a significant portfolio of loans and investments: * **Authorized Share Capital:** **Rs. 55,00,00,000** (55 Crore Equity Shares of **Rs. 1/-** each). * **Paid-up Share Capital:** **Rs. 55,00,00,000** (Fully paid). * **Loans Given:** **Rs. 1,427.00 Lakhs**. * **Investments:** **Rs. 4,555.84 Lakhs**. * **Reserves:** No amounts were transferred to reserves in recent periods due to **accumulated losses**. --- ### **Strategic Growth & Capital Expansion Mandate** To move beyond its current stagnant phase, the company has secured shareholder approval for a massive expansion of its financial leverage. This strategy is designed to fund future business requirements and strategic acquisitions. #### **New Financial Limits & Targets** | Provision | Limit / Target | Strategic Purpose | | :--- | :--- | :--- | | **Borrowing Limit** | **Rs. 100.00 Crores** | To support growth beyond existing credit facilities; includes **Domestic & Foreign** sources. | | **Investment & Lending** | **Rs. 100.00 Crores** | Mandate to provide **loans, guarantees, or securities** and acquire stakes in other bodies corporate. | | **Liquidity Strategy** | **Aggressive** | Increasing borrowing cap beyond the aggregate of **paid-up capital, free reserves, and securities premium**. | --- ### **Corporate Governance & Administrative Restructuring** The company has recently undergone a significant administrative overhaul to centralize management and improve oversight. * **Centralization of Offices:** As of **February 2026**, the company closed its New Delhi corporate office to consolidate all administrative and official communications at its **Registered Office in Ahmedabad**. * **Governance Structure:** The company maintains a lean structure with **no subsidiaries, associate companies, or joint ventures**. * **Board Composition:** The Board is considered duly constituted with a balance of **Executive, Non-Executive, and Independent Directors**. A certificate from a **Practicing Company Secretary** confirms no directors are disqualified by **SEBI** or the **MCA**. #### **Entity Data & Compliance Framework** * **Statutory Auditor:** **M/S. VRSK & Associates** (Appointed **Feb 13, 2026**). * **ISIN:** **INE560F01022**. * **Share Transfer:** Processes physical transfers within **15–21 days**; dematerialization is compulsory via **NSDL**. * **Related Party Transactions (RPT):** Conducted on an **arm’s length basis**; no materially significant RPTs with potential conflicts of interest reported. --- ### **Risk Factors & Regulatory Challenges** Investors should note significant recurring lapses in statutory compliance and financial stability. #### **Operational & Liquidity Risks** * **Material Uncertainty:** While management believes the company can meet liabilities falling due within **one year**, auditors have explicitly stated this is **not a guarantee** of future viability. * **Project Execution:** The company mitigates **commodity price risk** by executing projects through **third-party contractors**. #### **Statutory Non-Compliance Observations** The company has documented several recurring defaults regarding regulatory filings and appointments: * **Key Personnel:** Failure to appoint a **Company Secretary** (Section 203) and an **Internal Auditor** (Section 138). * **SEBI (LODR) Lapses:** Non-compliance regarding the publication of **Notice of Board Meetings**, **Notice of AGM**, and **Quarterly Results**. * **Data Governance:** Failure to maintain the **Structured Digital Database (SDD)** as per reporting requirements. * **ROC Filings:** Persistent delays in filing event-based **E-Forms** with the **Registrar of Companies**. --- ### **Summary for Investors** Johnson Pharmacare Limited is currently a "shell-active" entity with **zero operational revenue** but a substantial **investment and loan book**. Its future value is entirely dependent on the successful deployment of its **Rs. 100 Crore borrowing and investment mandate**. While the centralization of operations in Ahmedabad aims for efficiency, the company must resolve its **recurring regulatory non-compliance** and **widening cash losses** to establish long-term credibility in the capital markets.